RCT protocol development to evaluate MPPT in venous leg ulcers

开发 RCT 协议以评估腿部静脉溃疡中的 MPPT

• 批准号: 104920
• 金额: $ 3.19万
• 依托单位: WILLINGSFORD LIMITED
• 依托单位国家: 英国
• 项目类别: CR&D Bilateral
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104920
• 关键词: RCT; protocol; development; evaluate; MPPT

"The main reason wounds and ulcers have difficulty or fail to heal is infection. For the past decade, it has been standard medical practice to use antimicrobials to treat wound infections, but several clinical studies have shown that they have minimal effects and NICE and the FDA no longer encourage their use. Furthermore, both antibiotics and antiseptics strongly contribute to the creation of antimicrobial resistance, a global health problem.Micropore particle technology (MPPT) is a novel approach which acts as a passive immunotherapy for wound infection and healing. MPPT disrupts the weaponry bacteria and fungi use against the immune system with the result that the immune system regains control of the wound and the wound healing process. In a comparative clinical study MPPT removed wound infections and initiated healing 60% quicker than an antibiotic and an antiseptic and it reduced the number of hospitalisation days by 31%. Annually in the UK alone, 2.2 mill wounds require treatment causing direct costs to the NHS of £5.3 bn. Estimates indicate that MPPT can reduce the costs of wound care by 21% and can assist many patients who are strongly affected by wounds. MPPT is patented and expected to meet a global unmet clinical need. MPPT is not antimicrobial and will not contribute to the creation of resistance.A key factor in supporting the introduction of a new healthcare technology is to obtain an appraisal from NICE, which evaluates all data and offers an opinion on the health benefits of the approach. The purpose of this project is to prepare the first phase towards receiving such an appraisal. Once achieved, this will be used to support the introduction of the technology in the UK as well as to support export efforts as NICE recommendations are closely stuied in most countries worldwide."

“伤口和溃疡难以愈合或无法愈合的主要原因是感染。在过去的十年中，使用抗菌药物治疗伤口感染已成为标准的医疗实践，但多项临床研究表明，它们的效果微乎其微，NICE 和 FDA 不再鼓励使用它们。此外，抗生素和防腐剂都强烈促进抗菌药物耐药性的产生，而抗菌药物耐药性是全球健康的一个问题。 问题。微孔颗粒技术（MPPT）是一种新颖的方法，可作为伤口感染和愈合的被动免疫疗法。 MPPT 会破坏细菌和真菌对抗免疫系统的武器，从而使免疫系统重新控制伤口和伤口愈合过程。在一项比较临床研究中，MPPT 消除伤口感染并开始愈合的速度比抗生素和防腐剂快 60% 住院天数减少了 31%。仅在英国，每年就有 2.2 处伤口需要治疗，导致 NHS 的直接费用达 53 亿英镑。据估计，MPPT 可以将伤口护理成本降低 21%，并可以帮助许多受伤口严重影响的患者。 MPPT 已获得专利，有望满足全球未满足的临床需求。 MPPT 不具有抗菌作用，不会有助于产生 支持引入新医疗保健技术的一个关键因素是获得 NICE 的评估，该机构评估所有数据并就该方法的健康益处提供意见。该项目的目的是为接受此类评估做好第一阶段的准备。一旦实现，这将用于支持在英国引进该技术以及支持出口工作，因为全球大多数国家都在密切研究 NICE 的建议。”